Grace Therapeutics, Inc.
GRCEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 24, 2026 | Craig-Hallum | $4.00(+84%) | $2.17 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| TD Cowen | maintain | Buy | Apr 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.91 | $-0.13 | — | $400.0K |
| Jun 18, 2026 | $-0.07 | $-0.24 | — | $900.0K |
| Feb 12, 2026 | $-0.14 | $-0.09 | — | — |
| Nov 13, 2025 | $-0.08 | $-0.12 | — | — |
| Aug 12, 2025 | $-0.21 | $-0.22 | — | — |
| Jun 23, 2025 | $0.10 | $-0.20 | — | — |
| Feb 13, 2025 | $-0.26 | $-0.24 | — | — |
| Nov 13, 2024 | $-0.33 | $-0.33 | — | — |
News
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the Company's participation in upcoming healthcare industry and investor conferences during the month of November.
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C.
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.